Pneumonitis occurred in 7% (41/580) of adult patients with resected NSCLC who received KEYTRUDA as a single agent for adjuvant treatment of NSCLC, including fatal (0.2%), Grade 4 (0.3%), and Grade 3 (1%) adverse reactions.

Source: https://investingnews.com/preclinical-data-shows-arg-007-inhibits-one-of-the-main-causes-of-alzheimers-disease/

Pneumonitis occurred in 7% (41/580) of adult patients with resected NSCLC who received KEYTRUDA as a single agent for adjuvant treatment of NSCLC, including fatal (0.2%), Grade 4 (0.3%), and Grade 3 (1%) adverse reactions.

Source: https://investingnews.com/preclinical-data-shows-arg-007-inhibits-one-of-the-main-causes-of-alzheimers-disease/

This therapy targets advanced Non-Small Cell Lung Cancer (NSCLC) patients who have undergone chemotherapy and anti-PD-1 therapy.

Source: https://seekingalpha.com/article/4616359-iovance-biotherapeutics-evaluating-recent-developments-fda-feedback?source=feed_all_articles